The canine atopic dermatitis treatment market is poised for a considerable valuation bump, projected to increase from US$1,182.60 million in 2024 to US$1,620.50 million in 2034. The updated report indicates a Compound Annual Growth Rate (CAGR) of 3.20% from 2024 to 2034. This marks a significant decrease from the previous CAGR of 7.60% observed between 2019 and 2023.
Canine atopic dermatitis, a chronic inflammatory skin disease affecting dogs, has been a focus of attention in the pet healthcare sector. However, the market’s growth rate is experiencing a notable deceleration compared to previous years.
Secure Your Sample Report Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-4412
The market’s expansion is fueled by several key factors:
- Growing Pet Ownership and Increased Spending: Pet ownership continues to climb globally, with pet parents increasingly viewing their furry companions as valued members of the family. This translates into a greater willingness to invest in their pets’ health and well-being, including effective treatments for atopic dermatitis.
- Demand for Novel Therapeutics: Traditional treatments can have limitations. The market is witnessing a surge in demand for novel therapeutics, such as monoclonal antibodies, which offer a more targeted and potentially more effective approach to managing canine atopic dermatitis.
- Focus on Animal Comfort and Quality of Life: Pet owners are becoming more attuned to their dogs’ comfort and quality of life. Effective treatments for atopic dermatitis can significantly improve a dog’s overall well-being by reducing itching and inflammation.
Key Takeaways of Canine Atopic Dermatitis Treatment Market Study
- Immunosuppressant drugs that currently lead the market will lose their market share to monoclonal antibodies (mAb).
- Oral administration remains at the forefront of preferred drug intake method.
- Injectable drugs will witness a steady CAGR and will rise to prominence by 2029, surpassing oral administration.
- Retail pharmacies continue to hold the leading revenue share; veterinary clinics closing in.
- Gains in canine atopic dermatitis treatment market are concentrated in North America.
Top Growth Drivers
- Established players in human life sciences are investing significant pecuniary resources in veterinary science, ascertaining the market growth.
- Robust healthcare infrastructure and rising pet ownership are bolstering the growth of market in North America.
- Swift recovery and less side effects remain the growth levers fueling demand for injectable veterinary drugs.
- Increasing online availability and easy accessibility of medical information will continue to be the significant growth contributor.
Key Restraints
- Certain therapeutic agents are facing increasing resistance, which is limiting the demand for immunosuppressant drugs.
- Ineffectual management by healthcare providers is a major hindrance to market growth.
Get Familiar With Our Methodology:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-4412
Competitive Landscape
Leading players in global canine atopic dermatitis treatment market include, but are not limited to, Elanco Animal Health, Zoetis, Boragen Inc., and Immunomic Therapeutics Inc. Industry giants are focused on strategic alliances with regional players to boost their global presence. They continue to direct substantial resources towards regional acquisitions in order to fortify their market foothold. For instance, Zoetis acquired Nexvet Biopharma (2018) to accelerate the development of mAb therapies. This would enable the company to create new alternatives for treating canine atopic dermatitis. On the other hand, Elanco Animal Health acquired Boehringer Ingelheim Vetmedica, Inc. (2017), to innovate their range of rabies vaccines, canine and feline products.
Canine Atopic Dermatitis Treatment Market By Category
By Drug Class :
- Corticosteroids
- Immunosuppressants
- Antibiotics
- Antihistamines
- Emollients
- Essential Fatty Acids
- Antipruritics
- Monoclonal Antibodies
By Route of Administration :
- Topical
- Oral
- Injectable
By Distribution Channel :
- Veterinary Hospitals
- Veterinary Clinics
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
Obtain In-Depth Market Insights: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/4412
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
